A Prospective Natural History and Outcome Measure Validation Study of Congenital Myasthenic Syndromes
NCT ID: NCT06630650
Last Updated: 2025-10-21
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
75 participants
Study Classification
OBSERVATIONAL
Study Start Date
2025-05-12
Study Completion Date
2044-12-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background:
Congenital myasthenic syndromes (CMSs) are a group of inherited disorders that affect how the nerves communicate with muscles. These can cause many problems that affect how people can move and use their bodies.
Objective:
This is a natural history study to learn more about how CMSs affect the body and cause changes over time.
Eligibility:
People aged 6 months or older with a CMS. The study will focus on DOK7- and COLQ-related CMSs, as well as other forms.
Design:
Participants will have up to 7 visits in 5 years. At each visit, participants will undergo many tests, including:
Physical exam with blood and urine tests.
Tests of their heart and lung function.
Exams of the eyes, lungs, muscles, and nerves. These will be done with different specialists.
Exams of the arms and hands and of body use and movements. These will also be done with specialists.
Photos and videos may be taken.
Muscle ultrasound. Participants will lie still as a wand is rubbed over their skin.
Magnetic resonance imaging (MRI) scans. Participants will lie still on a bed that slides partway into a large tube. A parent or other person may remain in the room, too. The scan will take 60 minutes.
Electromyography (EMG). Participants will lie still or may be asked to move around. A machine will measure the electrical activity in their muscles.
An activity monitor may be placed on the participant s wrist, ankle, or hip for up to 2 weeks. The monitor is about the size of a wristwatch.
A sample of skin may be removed....
Congenital myasthenic syndromes (CMSs) are a group of inherited disorders that affect how the nerves communicate with muscles. These can cause many problems that affect how people can move and use their bodies.
Objective:
This is a natural history study to learn more about how CMSs affect the body and cause changes over time.
Eligibility:
People aged 6 months or older with a CMS. The study will focus on DOK7- and COLQ-related CMSs, as well as other forms.
Design:
Participants will have up to 7 visits in 5 years. At each visit, participants will undergo many tests, including:
Physical exam with blood and urine tests.
Tests of their heart and lung function.
Exams of the eyes, lungs, muscles, and nerves. These will be done with different specialists.
Exams of the arms and hands and of body use and movements. These will also be done with specialists.
Photos and videos may be taken.
Muscle ultrasound. Participants will lie still as a wand is rubbed over their skin.
Magnetic resonance imaging (MRI) scans. Participants will lie still on a bed that slides partway into a large tube. A parent or other person may remain in the room, too. The scan will take 60 minutes.
Electromyography (EMG). Participants will lie still or may be asked to move around. A machine will measure the electrical activity in their muscles.
An activity monitor may be placed on the participant s wrist, ankle, or hip for up to 2 weeks. The monitor is about the size of a wristwatch.
A sample of skin may be removed....
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
NCT06585605
Epilepsy in Children
Dyskinesias
Movement Disorders in Children
+7 more
RECRUITING
Surround Inhibition in Patients With Dystonia
NCT00029601
Dystonic Disorders
Healthy
COMPLETED
Impact of Sensory, Motor and Vestibular Deficit on the Postural Stability of CMT Patients
NCT06425952
Hereditary Neuropathy
RECRUITING
Transcranial Magnetic Stimulation (TMS) Studies of Dystonia
NCT00017875
Dystonic Disorder
Healthy
COMPLETED
Transcranial Magnetic Stimulation in Spino-Cerebellar Ataxia
NCT01975909
Spinocerebellar Ataxia
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Description:
This natural history and outcome measure validation study aims to longitudinally characterize the clinical manifestations of all congenital myasthenic syndromes (CMS), with a focus on DOK7 and COLQ-related CMS. Both are ultra-rare inherited disorders of the neuromuscular junction. This study will also assess the validity and interrater reliability of outcome measures to support clinical trial readiness in these populations.
Primary Objective:
Characterize baseline clinical manifestations and CMS disease course over one year.
Co-Primary Objective:
Assess the validity and interrater reliability of outcome measures in CMS.
Secondary Objectives:
Characterize the extended disease course of CMS (Years 2 through 5)
Exploratory Objectives:
Biomarker identification, accelerometer validation, and MCID estimation.
Primary Endpoints:
Change from baseline to Year 1 in the following (as age-appropriate and tolerated-performed in all participants unless age ranges specified):
* Physical strength
* MRC scale (all; as tolerated/developmentally appropriate)
* Quantitative muscle assessment of shoulder abductors, elbow flexors/extensors, hip flexors and knee extensors/flexors (QMA \>=7y)
* Myotools grip and pinch strength (\>=6y)
* Physical performance
* Six-minute walk test distance (\>=6y)
* Repeated 1 minute sit to stand (\>=2y)
* Performance of Upper Limb (PUL) (\>=2y)
* Time of outstretched arm (\>=2y)
* Disease severity
--Quantitative Myasthenia Gravis (QMG) Score (\>= 12y)
* Motor function \<2y
* Hammersmith infant neurological scale score (\<2y)
* Sitting balance score (\<2y)
* Motor function \>2y
* Motor function measure score (MFM20, 2-6y) (MFM32, \>=7y)
* Time to ascend four stairs, descend four stairs, supine to stand (\>=5y)
* Development
--Developmental motor scale quotients (\<5y)
* Pulmonary function \>=5y
* Forced vital capacity (FVC)
* Slow vital capacity (SVC)
* Forced vital capacity at 1 second (FEV1)
* Maximum inspiratory and expiratory pressures (MIP/MEP)
* End-tidal CO2 (ETCO2)
* Quality of life
* Myasthenia Quality of Life (PM-QOL15 \<18y, MG-QOL15 \>=18)
* PROMIS-57 Profile (\>=18y)
* PROMIS Ped-25 Profile (8-17y)
* PROMIS Parent Proxy CAT (5-7y)
* NeuroQoL (fatigue and upper and lower limb function domains, (\>=8y)
* MG-ADL (\>=18y)
* Serious adverse and disease-related events
* Narrative clinician description
* Causality assessment (related or unrelated to the research or disease)
* Event severity (CTCAE v5)
* Event MedDRA system organ class, and preferred term
Co-Primary Endpoints:
Interrater reliability in physical strength, physical performance, motor function, and quality of life primary endpoints.
Secondary Endpoints:
Change over time in primary endpoints (Years 2 through 5).
Exploratory Endpoints:
* Physical performance
* Timed up and go (TUG) test x3 (\>=2y)
* Wearable sensor metrics during physical performance tests
* Biomechanics
* Stride length, cadence, velocity captured in clinic by wearable device
* Stride velocity 95th centile
* Free-living physical activity
* Endpoints collected over 2-week data capture period will include:
* Number of sit-to-stand transitions
* Step count
* Average cadence per walking episode
* Number of falls
* Activity counts (light, moderate, vigorous, moderate to vigorous)
* Upper limb movements
* Proposal to use in infants/toddlers, use of one device/chest strap.
* Ophthalmology
* Marginal reflex distance (Ptosis)
* Pupillometry
* Ocular Motility utilizing Modified Goldmann Perimeter per NEI
* Quality of life
* CMS-ST- Infant/Young Child 6 months - \<=3 years of age
* CMS-ST Child/Adult (4 years - \<=18 years)
* Biomarkers
* Peripheral biomarkers
* Optional skin punch biopsy (fibroblast culture)
* Imaging
* Muscle MRI lower extremities (T1 and Dixon)
* Muscle ultrasound (echogenicity)
* Nerve function
--EMG/NCS (sfEMG and RNS)
* Measurement of AE burden
* Adverse Event Unit (AEU)
This natural history and outcome measure validation study aims to longitudinally characterize the clinical manifestations of all congenital myasthenic syndromes (CMS), with a focus on DOK7 and COLQ-related CMS. Both are ultra-rare inherited disorders of the neuromuscular junction. This study will also assess the validity and interrater reliability of outcome measures to support clinical trial readiness in these populations.
Primary Objective:
Characterize baseline clinical manifestations and CMS disease course over one year.
Co-Primary Objective:
Assess the validity and interrater reliability of outcome measures in CMS.
Secondary Objectives:
Characterize the extended disease course of CMS (Years 2 through 5)
Exploratory Objectives:
Biomarker identification, accelerometer validation, and MCID estimation.
Primary Endpoints:
Change from baseline to Year 1 in the following (as age-appropriate and tolerated-performed in all participants unless age ranges specified):
* Physical strength
* MRC scale (all; as tolerated/developmentally appropriate)
* Quantitative muscle assessment of shoulder abductors, elbow flexors/extensors, hip flexors and knee extensors/flexors (QMA \>=7y)
* Myotools grip and pinch strength (\>=6y)
* Physical performance
* Six-minute walk test distance (\>=6y)
* Repeated 1 minute sit to stand (\>=2y)
* Performance of Upper Limb (PUL) (\>=2y)
* Time of outstretched arm (\>=2y)
* Disease severity
--Quantitative Myasthenia Gravis (QMG) Score (\>= 12y)
* Motor function \<2y
* Hammersmith infant neurological scale score (\<2y)
* Sitting balance score (\<2y)
* Motor function \>2y
* Motor function measure score (MFM20, 2-6y) (MFM32, \>=7y)
* Time to ascend four stairs, descend four stairs, supine to stand (\>=5y)
* Development
--Developmental motor scale quotients (\<5y)
* Pulmonary function \>=5y
* Forced vital capacity (FVC)
* Slow vital capacity (SVC)
* Forced vital capacity at 1 second (FEV1)
* Maximum inspiratory and expiratory pressures (MIP/MEP)
* End-tidal CO2 (ETCO2)
* Quality of life
* Myasthenia Quality of Life (PM-QOL15 \<18y, MG-QOL15 \>=18)
* PROMIS-57 Profile (\>=18y)
* PROMIS Ped-25 Profile (8-17y)
* PROMIS Parent Proxy CAT (5-7y)
* NeuroQoL (fatigue and upper and lower limb function domains, (\>=8y)
* MG-ADL (\>=18y)
* Serious adverse and disease-related events
* Narrative clinician description
* Causality assessment (related or unrelated to the research or disease)
* Event severity (CTCAE v5)
* Event MedDRA system organ class, and preferred term
Co-Primary Endpoints:
Interrater reliability in physical strength, physical performance, motor function, and quality of life primary endpoints.
Secondary Endpoints:
Change over time in primary endpoints (Years 2 through 5).
Exploratory Endpoints:
* Physical performance
* Timed up and go (TUG) test x3 (\>=2y)
* Wearable sensor metrics during physical performance tests
* Biomechanics
* Stride length, cadence, velocity captured in clinic by wearable device
* Stride velocity 95th centile
* Free-living physical activity
* Endpoints collected over 2-week data capture period will include:
* Number of sit-to-stand transitions
* Step count
* Average cadence per walking episode
* Number of falls
* Activity counts (light, moderate, vigorous, moderate to vigorous)
* Upper limb movements
* Proposal to use in infants/toddlers, use of one device/chest strap.
* Ophthalmology
* Marginal reflex distance (Ptosis)
* Pupillometry
* Ocular Motility utilizing Modified Goldmann Perimeter per NEI
* Quality of life
* CMS-ST- Infant/Young Child 6 months - \<=3 years of age
* CMS-ST Child/Adult (4 years - \<=18 years)
* Biomarkers
* Peripheral biomarkers
* Optional skin punch biopsy (fibroblast culture)
* Imaging
* Muscle MRI lower extremities (T1 and Dixon)
* Muscle ultrasound (echogenicity)
* Nerve function
--EMG/NCS (sfEMG and RNS)
* Measurement of AE burden
* Adverse Event Unit (AEU)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Myasthenic Syndromes, Congenital
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COLQ-related CMS
Genetically confirmed COLQ-related CMS
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Male or female, aged \>= 6 months of age
* Clinically stable as evidenced by medical record review and remote screening questionnaire
* Genetically confirmed congenital myasthenic syndrome (pathogenic or likely pathogenic variants identified by CLIA testing in an established CMS-related gene including but not limited to DOK7, COLQ, CHRNE, RAPSN, CHAT, GFPT1, DPAGT1 OR pathogenic/likely pathogenic variant in combination with a variant of uncertain significance (VUS) AND additional clinical supporting evidence of CMS).
* Agreement to adhere to Lifestyle Considerations throughout study duration
* Ability of subject to understand and the willingness to provide informed consent (\>=18 years of age) and assent (\>=7 years of age).
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Male or female, aged \>= 6 months of age
* Clinically stable as evidenced by medical record review and remote screening questionnaire
* Genetically confirmed congenital myasthenic syndrome (pathogenic or likely pathogenic variants identified by CLIA testing in an established CMS-related gene including but not limited to DOK7, COLQ, CHRNE, RAPSN, CHAT, GFPT1, DPAGT1 OR pathogenic/likely pathogenic variant in combination with a variant of uncertain significance (VUS) AND additional clinical supporting evidence of CMS).
* Agreement to adhere to Lifestyle Considerations throughout study duration
* Ability of subject to understand and the willingness to provide informed consent (\>=18 years of age) and assent (\>=7 years of age).
Exclusion Criteria
* Received gene transfer therapy
* Pregnant women (prior to enrollment)
* Ongoing medical condition or medication use that is deemed by the Principal Investigator to interfere with the conduct or assessments of the study or safety of the subject.
* Pregnant women (prior to enrollment)
* Ongoing medical condition or medication use that is deemed by the Principal Investigator to interfere with the conduct or assessments of the study or safety of the subject.
Minimum Eligible Age
6 Months
Maximum Eligible Age
99 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carsten G Bonnemann, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Neurological Disorders and Stroke (NINDS)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
NIH Clinical Center Office of Patient Recruitment (OPR)
Role: primary
800-411-1222 ext. TTY dial 711
References
Explore related publications, articles, or registry entries linked to this study.
Brooks PJ, Ottinger EA, Portero D, Lomash RM, Alimardanov A, Terse P, Xu X, Chandler RJ, Geist Hauserman J, Esposito E, Bonnemann CG, Venditti CP, Austin CP, Pariser A, Lo DC. The Platform Vector Gene Therapies Project: Increasing the Efficiency of Adeno-Associated Virus Gene Therapy Clinical Trial Startup. Hum Gene Ther. 2020 Oct;31(19-20):1034-1042. doi: 10.1089/hum.2020.259. No abstract available.
Reference Type
BACKGROUND
Nicole S, Azuma Y, Bauche S, Eymard B, Lochmuller H, Slater C. Congenital Myasthenic Syndromes or Inherited Disorders of Neuromuscular Transmission: Recent Discoveries and Open Questions. J Neuromuscul Dis. 2017;4(4):269-284. doi: 10.3233/JND-170257.
Reference Type
BACKGROUND
Maggi L, Bernasconi P, D'Amico A, Brugnoni R, Fiorillo C, Garibaldi M, Astrea G, Bruno C, Santorelli FM, Liguori R, Antonini G, Evoli A, Bertini E, Rodolico C, Mantegazza R. Italian recommendations for diagnosis and management of congenital myasthenic syndromes. Neurol Sci. 2019 Mar;40(3):457-468. doi: 10.1007/s10072-018-3682-x. Epub 2018 Dec 15.
Reference Type
BACKGROUND
Bergamin E, Hallock PT, Burden SJ, Hubbard SR. The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization. Mol Cell. 2010 Jul 9;39(1):100-9. doi: 10.1016/j.molcel.2010.06.007.
Reference Type
BACKGROUND
Sigoillot SM, Bourgeois F, Lambergeon M, Strochlic L, Legay C. ColQ controls postsynaptic differentiation at the neuromuscular junction. J Neurosci. 2010 Jan 6;30(1):13-23. doi: 10.1523/JNEUROSCI.4374-09.2010.
Reference Type
BACKGROUND
Hallock PT, Xu CF, Park TJ, Neubert TA, Curran T, Burden SJ. Dok-7 regulates neuromuscular synapse formation by recruiting Crk and Crk-L. Genes Dev. 2010 Nov 1;24(21):2451-61. doi: 10.1101/gad.1977710.
Reference Type
BACKGROUND
Palace J, Lashley D, Newsom-Davis J, Cossins J, Maxwell S, Kennett R, Jayawant S, Yamanashi Y, Beeson D. Clinical features of the DOK7 neuromuscular junction synaptopathy. Brain. 2007 Jun;130(Pt 6):1507-15. doi: 10.1093/brain/awm072. Epub 2007 Apr 23.
Reference Type
BACKGROUND
Lee M, Beeson D, Palace J. Therapeutic strategies for congenital myasthenic syndromes. Ann N Y Acad Sci. 2018 Jan;1412(1):129-136. doi: 10.1111/nyas.13538.
Reference Type
BACKGROUND
McMacken GM, Spendiff S, Whittaker RG, O'Connor E, Howarth RM, Boczonadi V, Horvath R, Slater CR, Lochmuller H. Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome. Hum Mol Genet. 2019 Jul 15;28(14):2339-2351. doi: 10.1093/hmg/ddz059.
Reference Type
BACKGROUND
James MA. Use of the Medical Research Council muscle strength grading system in the upper extremity. J Hand Surg Am. 2007 Feb;32(2):154-6. doi: 10.1016/j.jhsa.2006.11.008. No abstract available.
Reference Type
BACKGROUND
Fernandez-Rhodes LE, Kokkinis AD, White MJ, Watts CA, Auh S, Jeffries NO, Shrader JA, Lehky TJ, Li L, Ryder JE, Levy EW, Solomon BI, Harris-Love MO, La Pean A, Schindler AB, Chen C, Di Prospero NA, Fischbeck KH. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 2011 Feb;10(2):140-7. doi: 10.1016/S1474-4422(10)70321-5. Epub 2011 Jan 6.
Reference Type
BACKGROUND
Bortolani S, Brusa C, Rolle E, Monforte M, De Arcangelis V, Ricci E, Mongini TE, Tasca G. Technology outcome measures in neuromuscular disorders: A systematic review. Eur J Neurol. 2022 Apr;29(4):1266-1278. doi: 10.1111/ene.15235. Epub 2022 Jan 10.
Reference Type
BACKGROUND
Bruggeman BS, Vincent HK, Chi X, Filipp SL, Mercado R, Modave F, Guo Y, Gurka MJ, Bernier A. Simple tests of cardiorespiratory fitness in a pediatric population. PLoS One. 2020 Sep 4;15(9):e0238863. doi: 10.1371/journal.pone.0238863. eCollection 2020.
Reference Type
BACKGROUND
Servais L, Mercuri E, Straub V, Guglieri M, Seferian AM, Scoto M, Leone D, Koenig E, Khan N, Dugar A, Wang X, Han B, Wang D, Muntoni F; SKIP-NMD Study Group. Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial. Nucleic Acid Ther. 2022 Feb;32(1):29-39. doi: 10.1089/nat.2021.0043. Epub 2021 Nov 17.
Reference Type
BACKGROUND
de Lattre C, Payan C, Vuillerot C, Rippert P, de Castro D, Berard C, Poirot I; MFM-20 Study Group. Motor function measure: validation of a short form for young children with neuromuscular diseases. Arch Phys Med Rehabil. 2013 Nov;94(11):2218-26. doi: 10.1016/j.apmr.2013.04.001. Epub 2013 Apr 18.
Reference Type
BACKGROUND
Berard C, Payan C, Hodgkinson I, Fermanian J; MFM Collaborative Study Group. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005 Jul;15(7):463-70. doi: 10.1016/j.nmd.2005.03.004.
Reference Type
BACKGROUND
Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987 Mar 19;316(12):719-24. doi: 10.1056/NEJM198703193161205.
Reference Type
BACKGROUND
Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998 May 13;841:769-72. doi: 10.1111/j.1749-6632.1998.tb11015.x. No abstract available.
Reference Type
BACKGROUND
Griffiths A, Toovey R, Morgan PE, Spittle AJ. Psychometric properties of gross motor assessment tools for children: a systematic review. BMJ Open. 2018 Oct 27;8(10):e021734. doi: 10.1136/bmjopen-2018-021734.
Reference Type
BACKGROUND
Richardson C, Smith T, Schaefer A, Turnbull D, Griffiths P. Ocular motility findings in chronic progressive external ophthalmoplegia. Eye (Lond). 2005 Mar;19(3):258-63. doi: 10.1038/sj.eye.6701488.
Reference Type
BACKGROUND
Chiang J, Mehta K, Amin R. Respiratory Diagnostic Tools in Neuromuscular Disease. Children (Basel). 2018 Jun 15;5(6):78. doi: 10.3390/children5060078.
Reference Type
BACKGROUND
Della Marina A, Wibbeler E, Abicht A, Kolbel H, Lochmuller H, Roos A, Schara U. Long Term Follow-Up on Pediatric Cases With Congenital Myasthenic Syndromes-A Retrospective Single Centre Cohort Study. Front Hum Neurosci. 2020 Dec 7;14:560860. doi: 10.3389/fnhum.2020.560860. eCollection 2020.
Reference Type
BACKGROUND
Prior DE, Cooper BA, Zhang B, Ghosh PS. Developing outcome measures of disease activity in pediatric myasthenia. Muscle Nerve. 2021 May;63(5):751-757. doi: 10.1002/mus.27208. Epub 2021 Feb 28.
Reference Type
BACKGROUND
Cella D, Choi SW, Condon DM, Schalet B, Hays RD, Rothrock NE, Yount S, Cook KF, Gershon RC, Amtmann D, DeWalt DA, Pilkonis PA, Stone AA, Weinfurt K, Reeve BB. PROMIS(R) Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains. Value Health. 2019 May;22(5):537-544. doi: 10.1016/j.jval.2019.02.004.
Reference Type
BACKGROUND
Cox ED, Connolly JR, Palta M, Rajamanickam VP, Flynn KE. Reliability and validity of PROMIS(R) pediatric family relationships short form in children 8-17 years of age with chronic disease. Qual Life Res. 2020 Jan;29(1):191-199. doi: 10.1007/s11136-019-02266-x. Epub 2019 Aug 10.
Reference Type
BACKGROUND
Varni JW, Thissen D, Stucky BD, Liu Y, Magnus B, Quinn H, Irwin DE, DeWitt EM, Lai JS, Amtmann D, Gross HE, DeWalt DA. PROMIS(R) Parent Proxy Report Scales for children ages 5-7 years: an item response theory analysis of differential item functioning across age groups. Qual Life Res. 2014 Feb;23(1):349-61. doi: 10.1007/s11136-013-0439-0. Epub 2013 Jun 6.
Reference Type
BACKGROUND
Finlayson S, Morrow JM, Rodriguez Cruz PM, Sinclair CD, Fischmann A, Thornton JS, Knight S, Norbury R, White M, Al-Hajjar M, Carboni N, Jayawant S, Robb SA, Yousry TA, Beeson D, Palace J. Muscle magnetic resonance imaging in congenital myasthenic syndromes. Muscle Nerve. 2016 Aug;54(2):211-9. doi: 10.1002/mus.25035. Epub 2016 Feb 22.
Reference Type
BACKGROUND
Ramdas S, Beeson D. Congenital myasthenic syndromes: where do we go from here? Neuromuscul Disord. 2021 Oct;31(10):943-954. doi: 10.1016/j.nmd.2021.07.400.
Reference Type
BACKGROUND
Benatar M, Sanders DB, Burns TM, Cutter GR, Guptill JT, Baggi F, Kaminski HJ, Mantegazza R, Meriggioli MN, Quan J, Wolfe GI; Task Force on MG Study Design of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Recommendations for myasthenia gravis clinical trials. Muscle Nerve. 2012 Jun;45(6):909-17. doi: 10.1002/mus.23330.
Reference Type
BACKGROUND
Troha Gergeli A, Neubauer D, Golli T, Butenko T, Loboda T, Maver A, Osredkar D. Prevalence and genetic subtypes of congenital myasthenic syndromes in the pediatric population of Slovenia. Eur J Paediatr Neurol. 2020 May;26:34-38. doi: 10.1016/j.ejpn.2020.02.002. Epub 2020 Feb 11.
Reference Type
BACKGROUND
Pane M, Coratti G, Brogna C, Mazzone ES, Mayhew A, Fanelli L, Messina S, D'Amico A, Catteruccia M, Scutifero M, Frosini S, Lanzillotta V, Colia G, Cavallaro F, Rolle E, De Sanctis R, Forcina N, Petillo R, Barp A, Gardani A, Pini A, Monaco G, D'Angelo MG, Zanin R, Vita GL, Bruno C, Mongini T, Ricci F, Pegoraro E, Bello L, Berardinelli A, Battini R, Sansone V, Albamonte E, Baranello G, Bertini E, Politano L, Sormani MP, Mercuri E. Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. PLoS One. 2018 Jun 20;13(6):e0199223. doi: 10.1371/journal.pone.0199223. eCollection 2018.
Reference Type
BACKGROUND
Mayhew AG, Coratti G, Mazzone ES, Klingels K, James M, Pane M, Straub V, Goemans N, Mercuri E; Pul Working Group. Performance of Upper Limb module for Duchenne muscular dystrophy. Dev Med Child Neurol. 2020 May;62(5):633-639. doi: 10.1111/dmcn.14361. Epub 2019 Sep 19.
Reference Type
BACKGROUND
Pierzchlewicz K, Kepa I, Podogrodzki J, Kotulska K. Spinal Muscular Atrophy: The Use of Functional Motor Scales in the Era of Disease-Modifying Treatment. Child Neurol Open. 2021 Apr 27;8:2329048X211008725. doi: 10.1177/2329048X211008725. eCollection 2021 Jan-Dec.
Reference Type
BACKGROUND
Burns TM, Sadjadi R, Utsugisawa K, Gwathmey KG, Joshi A, Jones S, Bril V, Barnett C, Guptill JT, Sanders DB, Hobson-Webb L, Juel VC, Massey J, Gable KL, Silvestri NJ, Wolfe G, Cutter G, Nagane Y, Murai H, Masuda M, Farrugia ME, Carmichael C, Birnbaum S, Hogrel JY, Nafissi S, Fatehi F, Ou C, Liu W, Conaway M. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve. 2016 Dec;54(6):1015-1022. doi: 10.1002/mus.25198. Epub 2016 Nov 7.
Reference Type
BACKGROUND
Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999 Apr 22;52(7):1487-9. doi: 10.1212/wnl.52.7.1487.
Reference Type
BACKGROUND
Ousmen A, Touraine C, Deliu N, Cottone F, Bonnetain F, Efficace F, Bredart A, Mollevi C, Anota A. Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review. Health Qual Life Outcomes. 2018 Dec 11;16(1):228. doi: 10.1186/s12955-018-1055-z.
Reference Type
BACKGROUND
Cornett KMD, Menezes MP, Bray P, Shy RR, Moroni I, Pagliano E, Pareyson D, Estilow T, Yum SW, Bhandari T, Muntoni F, Laura M, Reilly MM, Finkel RS, Eichinger KJ, Herrmann DN, Shy ME, Burns J; CMTPedS Study Group. Refining clinical trial inclusion criteria to optimize the standardized response mean of the CMTPedS. Ann Clin Transl Neurol. 2020 Sep;7(9):1713-1715. doi: 10.1002/acn3.51145. Epub 2020 Aug 6.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_002093-N.html
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
002093-N
Identifier Type: -
Identifier Source: secondary_id
10002093
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Low-frequency Repetitive Nerve Stimulation in Myotonic Dystrophy Type 1
NCT05662150
COMPLETED
NA
Physiologic Studies of Spasticity
NCT00014976
COMPLETED
Neuropsychological and Psychosocial Follow up of Children and Adolescents With Neuromuscular Disease
NCT02253290
RECRUITING
Functional Coupling of Cortico-Cortical and Cortico-Muscular Connections During Motor Movements: An Electrocorticographic Study of Ipsilateral Motor Control
NCT00036595
COMPLETED
EEG and EMG Studies of Hand Dystonia
NCT00025701
COMPLETED
Survey of Sensory and Motor Tricks in Focal Dystonia
NCT00054652
COMPLETED
Study of a Large Family With Congenital Mirror Movements : From Underlying Pathophysiology to Culprit Gene Identification PROJET " MOMIC "
NCT01075061
COMPLETED
NA
Proprioception and Sensorimotor Control in Hereditary Sensory and Autonomic Neuropathy
NCT02876939
COMPLETED
NA
Long-Term Motor Learning in Focal Hand Dystonia
NCT00325091
COMPLETED
Registry and Natural History of Epilepsy-Dyskinesia Syndromes
NCT06967727
RECRUITING
Effects of A Dual-Task Intervention in Postural Control in Multiple Sclerosis Patients
NCT04090996
UNKNOWN
NA
Neurophysiologic Study of Patient With Essential Tremor and Dystonic Tremor
NCT03041714
COMPLETED
Hearing and Balance Disorders in Peripheral Neuropathy
NCT05827419
TERMINATED
Evaluation of Cognitive Functions in 20 Patients With Type 1 Myotonic Dystrophy With Virtual Reality Approach
NCT06270186
WITHDRAWN
NA
Neurophysiology of Task-Specificity of Focal Hand Dystonia
NCT00309010
COMPLETED
Brain Control of Movements in Cerebral Palsy
NCT00076596
COMPLETED
Reliability of the Melbourne Assessment
NCT02595411
COMPLETED
Propensity to Develop Plasticity in the Parieto-Motor Networks in Dystonia From the Perspective of Abnormal High-Order Motor Processing
NCT02504905
COMPLETED
EARLY_PHASE1
Natural History in CCFDN and IBM Syndromes
NCT01902940
COMPLETED
Transcranial Magnetic Stimulation and Electrical Stimulation of Nerves to Study Focal Dystonia
NCT00050024
COMPLETED
Functional Connectivity in Primary Focal Dystonia
NCT01761903
COMPLETED
Interhemispheric Plasticity in Humans
NCT00120666
COMPLETED
Longitudinal Study of Cognition With Niemann-Pick Disease, Type C
NCT01899950
COMPLETED
Movement-Related Brain Networks Involved in Hand Dystonia
NCT00137384
COMPLETED